Back to discover
Drug

Meropenem

Approved · FDA
Emerging researchLate-stage development

Also known as Merrem, Vabomere, Meropenemum.

RxNorm29561ChEMBLCHEMBL4175954UNIIFV9J3JU8B1
2
Research papers
11
Active clinical trials
5
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG-RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE

Clinical trial2026-06-11Results expected Q1 2027 · ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

Clinical trial2026-05-22Results posted · ClinicalTrials.gov

"Comparing Efficacy of Intravenous Azithromycin and Meropenem for Extensively Drug-Resistant Enteric Fever: A Randomized Controlled Trial" (Pilot Study)

Clinical trial2026-05-08Results expected Q1 2027 · ClinicalTrials.gov

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study

Clinical trial2026-04-29Results expected Q2 2028 · ClinicalTrials.gov

An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer

Clinical trial2026-04-06Results posted · ClinicalTrials.gov

Label change: MEROPENEM (ANDA205835)

Regulatory2025-09-17FDA

Label change: MEROPENEM (ANDA205835)

Regulatory2025-07-25FDA

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.

Research2023-01-23The Pediatric infectious disease journal

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.

Research2021-05-02Molecules (Basel, Switzerland)

Label change: MEROPENEM (ANDA205835)

Regulatory2019-08-30FDA

Label change: MEROPENEM (ANDA205835)

Regulatory2019-08-30FDA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Meropenem
Aliases & brands
MerremVabomereMeropenemum
RxNorm CUI
29561
ChEMBL ID
CHEMBL4175954
UNII
FV9J3JU8B1
Regulatory jurisdictions
fda

Regulatory timeline

5 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2017-03-27
Latest approval
2017-03-27
Authorities
FDA
Total events
5
fdaU.S. Food and Drug Administration· 5 events
2025-09-17Label change
Label change: MEROPENEM (ANDA205835)
Evidence ↗
2025-07-25Label change
Label change: MEROPENEM (ANDA205835)
Evidence ↗
2019-08-30Label change
Label change: MEROPENEM (ANDA205835)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

104 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
104
registered trials across all phases
LATEST COMPLETION 2025
11
Active studies
11
Recruiting
75
Late-stage (III+)
64
Completed
29
Discontinued
PHASE DISTRIBUTIONn = 104
Phase 19Phase 1 / 27Phase 213Phase 2 / 33Phase 329Phase 435Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

RecruitingPH IVKey trialScandinavian Critical Care Trials Groupn=5,8002029

TREAT-GNB [CR-GNB]

RecruitingPH IVNational University of Singaporen=6002028

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study

Not yet recruitingPH IVBassett Healthcaren=8522028

Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial

RecruitingPH IVKey trialRambam Health Care Campusn=1,0842027

"Comparing Efficacy of Intravenous Azithromycin and Meropenem for Extensively Drug-Resistant Enteric Fever: A Randomized Controlled Trial" (Pilot Study)

RecruitingPH IVIndus Hospital and Health Networkn=402027

Recent completions

Trials that read out recently, adding to the completed evidence base.

Enhanced Clinical Recovery With Meropenem-Azithromycin Combination Therapy in Extensively Drug-Resistant Typhoid Feve

CompletedPH IVSheikh Zayed Medical Collegen=902025

A Phase 1, Open-Label, Single Center Study to Determine the Penetration of ANT3310 and Meropenem Into the Lung After Repeated Intravenous Administrations of MEM-ANT3310 in Healthy Adult Participants

CompletedPH IAntabion=262025

Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics & Safety of ANT3310 Combined With Meropenem Administered as a Single Intravenous Infusion to Adult Subjects With Renal Function Impairment

CompletedPH IAntabion=412025

Randomised Controlled Trial of Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Due to Enterobacteriaceae Showing Resistance to Third Generation Cephalosporins

CompletedPH IIIFundación Pública Andaluza para la gestión de la Investigación en Sevillan=3342024

A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

CompletedPH IIIWockhardtn=5302024

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

CompletedPH IVPakistan Navy Station Shifa Hospitaln=1502024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20212023
Major research themes4
Drug Design1Drug Resistance, Multiple, Bacterial1Pyelonephritis1Urinary Tract Infections1
Journals, researchers & institutions
Top journals
  • Molecules (Basel, Switzerland)1
  • The Pediatric infectious disease journal1
Leading researchers
  • Ashouri N1
  • Bensaci M1
  • Bradley JS1
  • Bruno CJ1
  • De Anda C1
  • Huntington JA1
  • Johnson MG1
  • Lonchar J1
Leading institutions
free-text, unnormalised
  • CHOC Children's Hospital1
  • School of Medicine1
  • University of California San Diego School of Medicine and Rady Children's Hospital of San Diego1
  • University of Pavia1

Related drugs

7 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cefiderocol

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Delafloxacin

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Eravacycline

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Plazomicin

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Pretomanid

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Sisomicin

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
Vaborbactam

Studied across 2 of the same disease areas as Meropenem in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.